Page 94 - 《中国药房》2022年8期

并发症的效用值测量研究较少，导致本研究纳入的文献 57-64.
有限，无法开展多因素 Meta 回归分析以确定单因素回 [14] PAPAIOANNOU D，BRAZIER J，PAISLEY S. NICE
归分析结果的稳健性，未来仍需基于更多负效用值测量 DSU technical support document 9：the identification，re-
文献开展影响因素研究，为负效用值测量研究规范的制 view and synthesis of health state utility values from the
订提供证据支持。 literature[EB/OL].[2022-02-01]. https：//pure.york.ac.uk/
参考文献 portal/en/publications/nice-dsu-technical-support-document-
[ 1 ] WOLOWACZ S E，BRIGGS A，BELOZEROFF V，et al. 19（4abca204-a8a5-4880-9cce-190049a1daf9）/export.html.
[15] PAPAIOANNOU D，BRAZIER J，PAISLEY S. Systema-
Estimating health-state utility for economic models in cli-
nical studies：an ISPOR good research practices task force tic searching and selection of health state utility values
from the literature[J]. Value Health，2010，16（4）：686-695.
report[J]. Value Health，2016，19（6）：704-719.
[ 2 ] 伍红艳.健康效用值测量研究[D].沈阳：沈阳药科大学， [16] MOK C H，KWOK H H Y，NG C S，et al. Health state uti-
lity values for type 2 diabetes and related complications in
2012.
[ 3 ] CRIVELLARO S，SOFER L，HALGRIMSON W R，et al. East and Southeast Asia：a systematic review and meta-
Optimized clinical decision-making：a configurable analysis[J]. Value Heal，2021，24（7）：1059-1067.
[17] HIGGINS JPT ，THOMAS J ，CHANDLER J ，et al.
Markov model for benign prostatic hyperplasia treatment[J].
Urology，2019，132：183-188. Cochrane handbook for systematic reviews of interven-
[ 4 ] York Health Economics Consortium. Disutility[EB/OL]. tions：version 6.2[EB/OL].[2021-02-11]. http：//www.trai-
[2022-02-01]. https：//yhec.co.uk/glossary/disutility/. ning.cochrane.org/handbook.
[ 5 ] PULLENAYEGUM E M，TARRIDE J E，XIE F，et al. Cal- [18] BEUSTERIEN K M，SZABO S M，KOTAPATI S，et al.
culating utility decrements associated with an adverse Societal preference values for advanced melanoma health
event：marginal Tobit and CLAD coefficients should be states in the United Kingdom and Australia[J]. Br J Can-
used with caution[J]. Med Decis Making，2011，31（6）： cer，2009，101（3）：387-389.
790-799. [19] SHIROIWA T，FUKUDA T，TSUTANI K. Health utility
[ 6 ] 刘心怡，陈文.奥希替尼用于 EGFR+晚期非小细胞肺癌 scores of colorectal cancer based on societal preference in
患者一线治疗的药物经济学评价[J].世界临床药物， Japan[J]. Qual Life Res，2009，18（8）：1095-1103.
2021，42（2）：135-142. [20] BEUSTERIEN K M，DAVIES J，LEACH M，et al. Popula-
[ 7 ] 刘国强，康朔，王欣晨.帕博利珠单抗一线治疗PD-L1高 tion preference values for treatment outcomes in chronic
表达的晚期非小细胞肺癌的药物经济学评价[J].中国药 lymphocytic leukaemia：a cross-sectional utility study[J].
房，2021，32（11）：1351-1356. Health Qual Life Outcomes，2010，8：50.
[ 8 ] FREEMAN K，CONNOCK M，CUMMINS E，et al. Fluo- [21] SWINBURN P，WANG J，CHANDIWANA D，et al. Elici-
rouracil plasma monitoring：systematic review and eco- tation of health state utilities in neuroendocrine tumours
nomic evaluation of the My5-FU assay for guiding dose [J]. J Med Econ，2012，15（4）：681-687.
adjustment in patients receiving fluorouracil chemothe- [22] FREDERIX G W，QUADRI N，HÖVELS A M，et al. Utility
rapy by continuous infusion[J]. Health Technol Assess， and work productivity data for economic evaluation of
2015，19（91）：1-321，v-vi. breast cancer therapies in the Netherlands and Sweden[J].
[ 9 ] NAFEES B，STAFFORD M，GAVRIEL S，et al. Health Clin Ther，2013，35（4）：e1-e7.
state utilities for non small cell lung cancer[J]. Health [23] KUCHUK I，BOUGANIM N，BEUSTERIEN K，et al.
Qual Life Outcomes，2008，6：84. Preference weights for chemotherapy side effects from the
[10] HAGIWARA Y，SHIROIWA T，SHIMOZUMA K，et al. perspective of women with breast cancer[J]. Breast Can-
Impact of adverse events on health utility and health-re- cer Res Treat，2013，142（1）：101-107.
lated quality of life in patients receiving first-line chemo- [24] TAM V C，KO Y J，MITTMANN N，et al. Cost-effective-
therapy for metastatic breast cancer：results from the ness of systemic therapies for metastatic pancreatic can-
SELECT BC study[J]. Pharmacoeconomics，2018，36（2）： cer[J]. Curr Oncol，2013，20（2）：e90-e106.
215-223. [25] SUN C，BROWN A J，JHINGRAN A，et al. Patient pre-
[11] SHINGLER S L，SWINBURN P，LLOYD A，et al. Elicita- ferences for side effects associated with cervical cancer
tion of health state utilities in soft tissue sarcoma[J]. Qual treatment[J]. Int J Gynecol Cancer，2014，24（6）：1077-
Life Res，2013，22（7）：1697-1706. 1084.
[12] SWINBURN P，LLOYD A，NATHAN P，et al. Elicitation [26] FORDHAM B A，KERR C，DE FREITAS H M，et al.
of health state utilities in metastatic renal cell carcinoma Health state utility valuation in radioactive iodine-refrac-
[J]. Curr Med Res Opin，2010，26（5）：1091-1096. tory differentiated thyroid cancer[J]. Patient Prefer Adhe-
[13] CHOU T C，CHIANG S C，KO Y. Health state utilities for rence，2015，9：1561-1572.
metastatic breast cancer in Taiwan[J]. Breast，2020，51： （下转第986页）

·980 · China Pharmacy 2022 Vol. 33 No. 8 中国药房 2022年第33卷第8期